Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02872857 · ClinicalTrials.gov registry record · Phase 1
Subarachnoid Hemorrhage Recovery And Galantamine
A Phase 1 study of Subarachnoid Hemorrhage, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT02872857 is a Phase 1 study of Subarachnoid Hemorrhage that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 60 participants, below the 3,585-participant average among 21 other Subarachnoid Hemorrhage trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02872857, a Phase 1 study of Subarachnoid Hemorrhage, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to examine the effects of the study drug--Galantamine-on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 8mg galantamine twice daily
- DRUG 12mg galantamine twice daily
Study Locations (2)
Texas
- Houston Methodist Hospital Texas Medical Center - Houston
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-09 |
| Est. Completion | 2019-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02872857
The ClinicalTrials.gov registry entry for NCT02872857 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,585-participant average among 21 other Subarachnoid Hemorrhage trials with a reported enrollment target (98% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02872857 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02872857 about?
NCT02872857 is a clinical study titled "Subarachnoid Hemorrhage Recovery And Galantamine". The purpose of this study is to examine the effects of the study drug--Galantamine-on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.
What is the current status of trial NCT02872857?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-09. Estimated completion is 2019-07-20.
What conditions does trial NCT02872857 study?
This clinical trial studies the following conditions: Subarachnoid Hemorrhage.
What interventions are being tested in trial NCT02872857?
The interventions under investigation include: Placebo (DRUG), 8mg galantamine twice daily (DRUG), 12mg galantamine twice daily (DRUG).
Who is sponsoring clinical trial NCT02872857?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02872857 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subarachnoid Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
RECRUITING · Phase 1
-
Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?
RECRUITING · Phase 1
-
A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm
COMPLETED · Phase 1
-
Remote Ischemic Preconditioning in Subarachnoid Hemorrhage
COMPLETED · Phase 1
-
AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.